QNTM MEXC RealStocks
Own real QNTM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 19:23:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Quantum Biopharma Ltd (QNTM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.64, with a market capitalization of $15.60M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.34 to $12.42. This page covers its latest market performance, valuation, price trends and company information.
$15.60M | |
$1.75 | |
$1.88 | |
$1.34 | |
$1.78 | |
57.65K | |
153.96K | |
-- | |
$12.42 | |
$1.34 | |
-- | |
-- |
Quantum Biopharma Ltd (QNTM) is currently trading at $1.64 as of 2026-11-13 19:16:00, down 6.29% ($0.11) from the previous close of $1.78
During today's regular trading session, QNTM has traded between $1.34 and $1.88, with a trading volume of 57.65K shares. The current price is near the middle of today's range.
Over the past seven days, Quantum Biopharma Ltd (QNTM) moved from $2.11 to $1.64, representing a decline of 22.27% ($0.47).
The stock traded between $1.34 and $2.31 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 109.63 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.7%
QNTM is currently trading at $1.64, placing it 2.7% of the way from its 52-week low of $1.34 to its 52-week high of $12.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Quantum Biopharma Ltd (QNTM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to QNTM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between QNTM shares and USD.
QNTM Shares to USD
1.00 QNTM shares = 1.64 USD
Calculations are estimates based on the latest available price and are for reference only.